RENOVORX
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market. RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of intervention... al radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.
RENOVORX
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2009-01-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.renovorx.com
Total Employee:
1+
Status:
Active
Contact:
650-284-4433
Total Funding:
10.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Boston Scientific
Boston Scientific investment in Series D - RenovoRx
Astia Angels
Astia Angels investment in Series D - RenovoRx
btov Partners
btov Partners investment in Series D - RenovoRx
Golden Seeds
Golden Seeds investment in Series D - RenovoRx
Portfolia
Portfolia investment in Series A - RenovoRx
Barbara Clarke
Barbara Clarke investment in Series A - RenovoRx
Plug and Play
Plug and Play investment in Series C - RenovoRx
Next Wave/Portfolia Angel Fund
Next Wave/Portfolia Angel Fund investment in Series C - RenovoRx
Golden Seeds
Golden Seeds investment in Series C - RenovoRx
Astia Angels
Astia Angels investment in Series C - RenovoRx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-19 | RenovoRx Appoints James Ahlers as Chief Financial Officer |
Official Site Inspections
http://www.renovorx.com Semrush global rank: 4.7 M Semrush visits lastest month: 2.05 K
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "RenovoRx"
RenovoRx - Crunchbase Company Profile & Funding
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral …See details»
About Us - RenovoRx
RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate is a novel oncology …See details»
Leadership Team - RenovoRx
Shaun R. Bagai Chief Executive Officer. Mr. Bagai has served as our Chief Executive Officer and director since June 2014. Prior to joining us, Mr. Bagai led Global Market Development for …See details»
RenovoRX, Inc. (RNXT)
Mar 20, 2025 RenovoRX, Inc. 2570 W. El Camino Real Suite 320 Mountain View, CA 94040 [email protected]. Investor Relations. KCSA Strategic Communications Valter Pinto or Jack …See details»
Company Information :: RenovoRX, Inc. (RNXT)
RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology …See details»
RenovoRx (Nasdaq: RNXT) - LinkedIn
RenovoRx (Nasdaq: RNXT) is a life sciences company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to …See details»
RenovoRx – Developing Innovative Solutions for …
RenovoRx’s patented TAMP therapy platform is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic IV …See details»
RenovoRx, Inc. - AnnualReports.com
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to …See details»
RenovoRx (RNXT) Company Profile & Description - Stock Analysis
Aug 26, 2021 RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer …See details»
RenovoRx - Org chart - The Org
Explore RenovoRx's organizational chart. Discover current team members including executives, board members, and advisors.See details»
RenovoRx 2025 Company Profile: Stock Performance
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing …See details»
Q1 2025 RenovoRx Inc Earnings Call - Yahoo Finance Canada
1 day ago For a detailed discussion of some of the material risks and uncertainties facing RenovoRx, I refer you to the company's annual report on Form 10-K for the year ended …See details»
RenovoRx: Revenue, Worth, Valuation & Competitors 2025
About RenovoRx. RenovoRx is a Medical Equip related company with 20 employees an estimated revenue of $4.5M, and. It has 10 competitors including AdviNow Medical, WestPac Surgical …See details»
RenovoRx Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. It offers a therapy platform, RenovoRx Trans …See details»
RenovoRx Closes $11.1 Million Private Placement, Providing Cash …
Apr 15, 2024 Shaun Bagai, Chief Executive Officer of RenovoRx, stated, “We believe our recent financing achievements mark a critical milestone for RenovoRx. Our April and January 2024 …See details»
RenovoRx - Overview, News & Similar companies | ZoomInfo.com
May 30, 2024 RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. …See details»
Investor Relations - RenovoRx
Jul 13, 2022 This innovative therapy utilizes RenovoRx’s lead product candidate, RenovoGem ™ (intra-arterial gemcitabine in combination with the proprietary RenovoCath ® delivery …See details»
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany Participants. Valter Pinto - IR. Ramtin Agah - Founder and Chief Medical Officer. …See details»
RenovoRx Reports First Quarter 2025 Financial Results and …
1 day ago MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted …See details»
RenovoRx Increases U.S. Production of RenovoCath® Devices to …
Apr 16, 2025 Separately, RenovoRx announced that during its most recent open trading window, members of the management team and Board of Directors purchased an aggregate of …See details»